scholarly journals Potential role for peroxisome proliferator-activated receptor γ in regulating luteal lifespan in the rat

Reproduction ◽  
2007 ◽  
Vol 133 (1) ◽  
pp. 187-196 ◽  
Author(s):  
Nicole Tinfo ◽  
Carolyn Komar
Keyword(s):  
Corpora Lutea ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor ◽  
Luteal Cells ◽  
Progesterone Production ◽  
Chain Cleavage ◽  
Major Player ◽  
Luteal Tissue ◽  
Pparγ Agonists

Peroxisome proliferator-activated receptor γ (PPARγ) has been shown to stimulate progesterone production by bovine luteal cells. We previously reported higher expression of PPARγ in old compared with new luteal tissue in the rat. The following studies were conducted to determine the role of PPARγ in rat corpora lutea (CL) and test the hypothesis that PPARγ plays a role in the metabolism of progesterone and/or luteal lifespan. Ovaries were removed from naturally cycling rats throughout the estrous cycle, and pseudopregnant rats. mRNA for PPARγ and P450 side-chain cleavage (SCC) was localized in luteal tissue byin situhybridization, and protein corresponding to PPARγ and macrophages identified by immunohistochemistry. Luteal tissue was cultured with agonists (ciglitazone, prostaglandin J2) or an antagonist (GW-9662) of PPARγ. Progesterone was measured in media by RIA and levels of mRNA for 20α-hydroxysteriod dehydrogenase (HSD) and bcl-2 were measured in luteal tissue after culture by RT-PCR. An inverse relationship existed between the expression of mRNA for SCC and PPARγ. There was no effect of PPARγ agonists or the antagonist on luteal progesterone productionin vitro, or levels of mRNA for 20α-HSD. PPARγ protein was localized to the nuclei of luteal cells and did not correspond with the presence of macrophages. In new CL, ciglitazone decreased mRNA for bcl-2 on proestrus, estrus, and metestrus. Interestingly, GW-9662 also decreased mRNA for bcl-2 on proestrus and diestrus in old and new CL, and on metestrus in new CL. These data indicate that PPARγ is not a major player in luteal progesterone production or metabolism but may be involved in regulating luteal lifespan.

scholarly journals Peroxisome proliferator-activated receptor-γ in cystic fibrosis lung epithelium

2008 ◽  
Vol 295 (2) ◽  
pp. L303-L313 ◽  
Author(s):  
Aura Perez ◽  
Anna M. van Heeckeren ◽  
David Nichols ◽  
Sanhita Gupta ◽  
Jean F. Eastman ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Epithelial Cells ◽  
Acute Infection ◽  
Airway Epithelial Cells ◽  
Peroxisome Proliferator ◽  
Airway Epithelial ◽  
Peroxisome Proliferator Activated Receptor ◽  
Pparγ Agonists

The pathophysiology of cystic fibrosis (CF) inflammatory lung disease is not well understood. CF airway epithelial cells respond to inflammatory stimuli with increased production of proinflammatory cytokines as a result of increased NF-κB activation. Peroxisome proliferator-activated receptor-γ (PPARγ) inhibits NF-κB activity and is reported to be reduced in CF. If PPARγ participates in regulatory dysfunction in the CF lung, perhaps PPARγ ligands might be useful therapeutically. Cell models of CF airway epithelium were used to evaluate PPARγ expression and binding to NF-κB at basal and under conditions of inflammatory stimulation by Pseudomonas aeruginosa or TNFα/IL-1β. An animal model of CF was used to evaluate the potential of PPARγ agonists as therapeutic agents in vivo. In vitro, PPARγ agonists reduced IL-8 and MMP-9 release from airway epithelial cells in response to PAO1 or TNFα/IL-1β stimulation. Less NF-κB bound to PPARγ in CF than normal cells, in two different assays; PPARγ agonists abrogated this reduction. PPARγ bound less to its target DNA sequence in CF cells. To test the importance of the reported PPARγ inactivation by phosphorylation, we observed that inhibitors of ERK, but not JNK, were synergistic with PPARγ agonists in reducing IL-8 secretion. In vivo, administration of PPARγ agonists reduced airway inflammation in response to acute infection with P. aeruginosa in CF, but not wild-type, mice. In summary, PPARγ inhibits the inflammatory response in CF, at least in part by interaction with NF-κB in airway epithelial cells. PPARγ agonists may be therapeutic in CF.

Effects of prolactin on steroid production by human luteal cells in vitro

1983 ◽  
Vol 96 (3) ◽  
pp. 499-503 ◽  
Author(s):  
G. J. S. Tan ◽  
J. S. G. Biggs
Keyword(s):  
Menstrual Cycle ◽  
Ovarian Function ◽  
Chorionic Gonadotrophin ◽  
Human Chorionic Gonadotrophin ◽  
Corpora Lutea ◽  
Short Term ◽  
Steroid Production ◽  
Luteal Cells ◽  
Progesterone Production

The effects of prolactin on steroidogenesis were studied in dispersed luteal cells prepared from human corpora lutea of the menstrual cycle. Prolactin, at concentrations of 0·1–1000 ng/ml, had no effect on progesterone production by luteal cells during short-term incubation (3 h). However, in two out of five corpora lutea, higher concentrations of prolactin (100 and 1000 ng/ml) significantly reduced the oestradiol-17β production induced by human chorionic gonadotrophin (hCG; 10 i.u./ml); lower doses of prolactin had little effect. In the remaining corpora lutea, prolactin failed to affect either basal or hCG-induced production of oestradiol-17β. These results are discussed in relation to the mechanism by which prolactin influences human ovarian function.

Effect of ovine conceptus and endometrial secretory products on luteal progesterone production in vitro

1986 ◽  
Vol 64 (12) ◽  
pp. 1556-1560
Author(s):  
D. W. Beckner ◽  
J. G. Manns
Keyword(s):  
Luteinizing Hormone ◽  
Conditioned Medium ◽  
Endometrial Tissue ◽  
Minimal Essential Medium ◽  
Luteal Cells ◽  
Endometrial Cells ◽  
Progesterone Production ◽  
Luteal Tissue ◽  
Secretory Products

The objectives of this study were the following: (i) to determine if ovine conceptus secretory products are directly luteotrophic to luteal tissue in vitro and (ii) to determine if ovine conceptus secretory products stimulate endometrial tissue to secrete a luteotropin in vitro. Conceptus-conditioned medium (CCM) was prepared by incubating day 14 ovine conceptuses in minimal essential medium (MEM) for 24 h and harvesting the supernatant. Endometrium-conditioned CCM (E-CCM) and endometrium-conditioned medium (ECM) were prepared by incubating dispersed ovine endometrial cells from day 9–10 cycling ewes in CCM or MEM, respectively, for 16 h and harvesting the supernatants. Media, conditioned as described, were incubated at various dilutions with dispersed luteal cells from day 9–10 cycling ewes for 90 min or 6 h in the absence or presence of 50 ng/mL ovine luteinizing hormone (oLH). CCM did not alter progesterone (P4) production in the 90-min incubation but did increase (p < 0.05) P4 production in the 6-h incubation (1:4, 1:8, 1:16 dilutions). When coincubated with oLH, CCM did not increase P4 production above that stimulated by oLH alone. The effect of E-CCM was similar to CCM or ECM and did not differ significantly from basal. It is concluded that the day 14 ovine conceptus does secrete a factor that is able to directly stimulate P4 secretion by luteal cells in a 6-h, but not a 90-min, incubation. Conceptus secretory products did not stimulate endometrial cells to secrete a luteotropin. The data are consistent with the suggestion that the luteotrophic factor secreted by the conceptus is a prostaglandin of the E series.

scholarly journals Assessment of the mechanism by which prolactin stimulates progesterone production by early corpora lutea of pigs

1998 ◽  
Vol 159 (2) ◽  
pp. 201-209 ◽  
Author(s):  
RE Ciereszko ◽  
BK Petroff ◽  
AC Ottobre ◽  
Z Guan ◽  
BT Stokes ◽  
...  
Keyword(s):  
Inositol Phosphate ◽  
Specific Binding ◽  
Positive Control ◽  
Free Calcium ◽  
Corpora Lutea ◽  
Pkc Inhibitor ◽  
Luteal Cells ◽  
Progesterone Production ◽  
Progesterone Secretion

Previously, we reported that administration of prolactin (PRL) during the early luteal phase in sows increases plasma progesterone concentrations. In the current study, we searched for the mechanisms by which PRL exerts this luteotrophic effect. The objectives of the study were (1) to examine the effect of PRL and/or low-density lipoproteins (LDL) on progesterone production by porcine luteal cells derived from early corpora lutea, and (2) to assess the ability of PRL to activate phosphoinositide-specific phospholipase C (PI-PLC) and protein kinase C (PKC) in these luteal cells. Ovaries with early corpora lutea (day 1-2 of the oestrous cycle) were obtained from the slaughterhouse. Progesterone production by dispersed luteal cells was measured after treatment with PRL, phorbol 12-myristate 13-acetate or inhibitors of PKC in the presence or absence of LDL. LDL increased progesterone concentration in the incubation medium (304.5 vs 178.6 ng/ml in control, P<0.05). PRL augmented LDL-stimulated progesterone secretion by luteal cells (to 416 ng/ml, P<0.05), but PRL alone did not affect progesterone production (209.6 ng/ml, P>0.05). Staurosporine, a PKC inhibitor, inhibited progesterone secretion stimulated by the combined action of LDL and PRL; however, such inhibition was not demonstrated when cells were treated with the PKC inhibitor, H-7. PKC activation was assessed by measuring the specific association of [H]phorbol dibutyrate (H-PDBu) with luteal cells after treatment with PRL or ionomycin (a positive control). PRL and ionomycin increased H-PDBu-specific binding in early luteal cells by 28+/-5.5% (within 5 min) and 70.2+/-19.3% (within 2 min) over control binding respectively (P<0.05). In addition, PRL did not augment the LDL-stimulated progesterone production in PKC-deficient cells. In contrast with PKC, total inositol phosphate accumulation, as well as intracellular free calcium concentrations, were not affected by PRL in the current study. We conclude that PRL, in the presence of LDL, stimulates progesterone production by early corpora lutea in vitro. Moreover, PRL appears to activate PKC, but not PI-PLC, in these cells. Thus intracellular transduction of the PRL signal may involve activation of PKC that is not dependent on PI-PLC.

PPARγ Agonists in Combination Cancer Therapies

2020 ◽  
Vol 20 (3) ◽  
pp. 197-215
Author(s):  
Piotr Mrowka ◽  
Eliza Glodkowska-Mrowka
Keyword(s):  
Targeted Therapy ◽  
Therapeutic Potential ◽  
Pharmacological Therapy ◽  
Treatment Modalities ◽  
Peroxisome Proliferator ◽  
Tumoricidal Activity ◽  
Peroxisome Proliferator Activated Receptor ◽  
Anticancer Efficacy ◽  
Pparγ Agonists

: Peroxisome proliferator-activated receptor-gamma (PPARγ) is a nuclear receptor acting as a transcription factor involved in the regulation of energy metabolism, cell cycle, cell differentiation, and apoptosis. These unique properties constitute a strong therapeutic potential that place PPARγ agonists as one of the most interesting and widely studied anticancer molecules. : Although PPARγ agonists exert significant, antiproliferative and tumoricidal activity in vitro, their anticancer efficacy in animal models is ambiguous, and their effectiveness in clinical trials in monotherapy is unsatisfactory. However, due to pleiotropic effects of PPARγ activation in normal and tumor cells, PPARγ ligands interact with many antitumor treatment modalities and synergistically potentiate their effectiveness. The most spectacular example is a combination of PPARγ ligands with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). In this setting, PPARγ activation sensitizes leukemic stem cells, resistant to any previous form of treatment, to targeted therapy. Thus, this combination is believed to be the first pharmacological therapy able to cure CML patients. : Within the last decade, a significant body of data confirming the benefits of the addition of PPARγ ligands to various antitumor therapies, including chemotherapy, hormonotherapy, targeted therapy, and immunotherapy, has been published. Although the majority of these studies have been carried out in vitro or animal tumor models, a few successful attempts to introduce PPARγ ligands into anticancer therapy in humans have been recently made. In this review, we aim to summarize shines and shadows of targeting PPARγ in antitumor therapies.

Prolactin stimulates steroidogenesis by human luteal tissue in vitro

1984 ◽  
Vol 103 (1) ◽  
pp. 107-110 ◽  
Author(s):  
M. G. Hunter
Keyword(s):  
Corpus Luteum ◽  
Luteal Phase ◽  
Chorionic Gonadotrophin ◽  
Human Chorionic Gonadotrophin ◽  
Corpora Lutea ◽  
Progesterone Production ◽  
Luteal Tissue ◽  
Oestradiol Production ◽  
Human Corpus Luteum

ABSTRACT Human luteal tissue recovered from varying stages of the luteal phase was minced and incubated for 3 h and the effect of human chorionic gonadotrophin (hCG), prolactin and hCG + prolactin on progesterone and oestradiol production measured. While hCG generally enhanced both progesterone and oestradiol synthesis, prolactin alone at either 20 or 200 μg/l had no significant effect on steroidogenesis. When prolactin was added along with hCG in four of six corpora lutea, however, progesterone production significantly increased and in three of six corpora lutea oestradiol production was increased above that induced by hCG alone. It is concluded that prolactin may play some role in the control of steroidogenesis by the human corpus luteum. J. Endocr. (1984) 103, 107–110

Effects of oestradiol and prolactin on progesterone production by rhesus monkey luteal cells in vitro

1985 ◽  
Vol 108 (2) ◽  
pp. 266-272 ◽  
Author(s):  
Richard F. Laherty ◽  
Daniel Rotten ◽  
May Yamamoto ◽  
Robert B. Jaffe
Keyword(s):  
Cyclic Adenosine Monophosphate ◽  
Adenosine Monophosphate ◽  
Inhibitory Effect ◽  
Corpora Lutea ◽  
Experimental Conditions ◽  
Luteal Cells ◽  
Progesterone Production ◽  
Mechanical Disruption ◽  
Progesterone Secretion

Abstract. The effects of oestradiol and prolactin (Prl) on progesterone production by dispersed monkey luteal cells were examined. Corpora lutea were recovered from monkeys 5–7 days following ovulation induction during the puerperium. The tissue was dispersed by collagenase and mechanical disruption. The resulting cells were incubated in Dulbecco's modified Eagle's medium, containing the hormones to be tested, for 3 h at 37°C. The medium was removed and assayed for progesterone by RIA. Human luteinizing hormone (hLH) produced a significant, dose-related increase in progesterone secretion that was comparable to that produced by dibutyryl cyclic adenosine monophosphate. Human follicle stimulating hormone (hFSH) had no effect upon progesterone production by the luteal cells. Oestradiol (100–10 000 pg/ml) produced a significant, dose-related decrease in both basal and hLH-stimulated progesterone production. Ovine Prl (oPrl) had neither a stimulatory nor an inhibitory effect upon basal progesterone secretion at doses up to 1000 ng/ml. Further, oPrl did not affect hLH-stimulated progesterone production. We conclude that oestradiol is a potent inhibitor of luteal progesterone secretion in vitro and that Prl does not inhibit progesterone production in the primate corpus luteum under these experimental conditions.

Luteotrophic factors in hyperstimulated pseudopregnant rabbit: II – High sensitivity to hCG of luteal tissue and small luteal cells

1997 ◽  
Vol 154 (2) ◽  
pp. 259-265 ◽  
Author(s):  
R K Arioua ◽  
A Benhaïm ◽  
C Féral ◽  
P Leymarie
Keyword(s):  
High Sensitivity ◽  
Chorionic Gonadotrophin ◽  
Small Cells ◽  
Corpora Lutea ◽  
Aromatase Activity ◽  
Large Contribution ◽  
Luteal Cells ◽  
Progesterone Secretion ◽  
Luteal Tissue

Abstract Previous studies on rabbit corpus luteum (CL) led to the conclusion that the luteotrophic complex, in rabbit, may include LH as well as oestradiol for normal luteal function. However, the requirement for LH is controversial. We have recently demonstrated the existence of a human chorionic gonadotrophin (hCG)-stimulated aromatase activity in cultured corpora lutea from a hyperstimulated pseudopregnant rabbit model, which develops a large number of corpora lutea, with only a few or no follicles in the ovaries. The present study was undertaken to investigate the in vitro responsiveness to hCG, dibutyryl cAMP (dbcAMP) and oestradiol of those corpora lutea. Pseudopregnancy (PP) was induced in rabbits by i.m. injection of 200 IU equine chorionic gonadotrophin daily for 2 days followed on day 4 by i.m. injection of 200 IU hCG (day 0 of PP). Luteal tissue and small and large luteal cells obtained at days 5 and 9 of PP were cultured for 24 h or during several days respectively with or without hCG, dbcAMP or oestradiol. Basal progesterone secretion was 3·6- and 22-fold higher in large cells compared with small ones at day 5 and 9 of PP respectively. When stimulated by small doses of hCG, luteal tissue responded by a 5-fold increase in progesterone secretion. Small cells produced four times higher amounts of progesterone than controls in the presence of 1 mIU/ml hCG and more than ten times in the presence of 0·1 IU/ml hCG, whereas large cells were insensitive to hCG stimulation. dbcAMP mimicked the effect of hCG on progesterone secretion by luteal tissue and luteal cells and oestradiol stimulated basal progesterone secretion in both small and large luteal cells. Given the large contribution of non stimulated large cells to luteal progesterone production and the remarkably high sensitivity of luteal tissue to gonadotrophin in vitro it seems that interactions between the two types of cells might occur during LH stimulation. Our results suggest that LH could participate in the luteotrophic complex at least in part through the stimulation of endogenous oestradiol production by luteal cells. Journal of Endocrinology (1997) 154, 259–265

Sign in / Sign up

Export Citation Format

Share Document